Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
Retrieved on:
Tuesday, March 22, 2022
Company, Cancer, Cell, Survivor, University, MD Anderson Cancer Center, Marketing, Immunotherapy, Society, Clinical trial, OCCC, Reproductive medicine, PP2A, James Hinchcliffe, Survival, Research, Neoplasm, Ovarian cancer, MD, Securities Exchange Act of 1934, Securities Act of 1933, Primary peritoneal carcinoma, CA, U.S. Securities and Exchange Commission, GLOBE, Society of Gynecologic Oncology, Gynecologic Oncology (journal), CTLA4, SGO, Drug Quality and Security Act, Terminology, Patient, Disease, Toxicity, Vaccine, Pharmaceutical industry, PPP2R1A
PASADENA, CA, March 22, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear cell carcinoma (OCCC) treated with immune checkpoint inhibitors lived significantly longer (had increased overall survival) than most patients with the same disease treated with the same regimens.
Key Points:
- Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their cancers (loss-of-function mutations) correlates with marked clinical benefit.
- Median overall survival was not reached in seven patients with hotspot inactivation mutations in PPP2R1A versus 6.4 months in the 21 patients without such mutations (p=0.018; HR=0.13 (95% CI: 0.02-0.95).
- Of note in several patients, response or prolonged disease stabilization leading to longer survival occurred after initial progression.
- This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at www.sec.gov/edgar.shtml